In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group

In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group

The in vitro activities of lascufloxacin were evaluated by comparison with seven reference compounds using 412 clinical isolates of anaerobes and Streptococcus anginosus group. Lascufloxacin showed potent and broad antibacterial activities greater than those of existing quinolones against the clinic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anaerobe 2018-12, Vol.54, p.61-64
Hauptverfasser: Yamagishi, Yuka, Matsukawa, Yoko, Suematsu, Hiroyuki, Mikamo, Hiroshige
Format: Artikel
Sprache:eng
Schlagworte:
Anaerobe
Fluoroquinolone
Lascufloxacin
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 64
container_issue
container_start_page 61
container_title Anaerobe
container_volume 54
creator Yamagishi, Yuka
Matsukawa, Yoko
Suematsu, Hiroyuki
Mikamo, Hiroshige
description The in vitro activities of lascufloxacin were evaluated by comparison with seven reference compounds using 412 clinical isolates of anaerobes and Streptococcus anginosus group. Lascufloxacin showed potent and broad antibacterial activities greater than those of existing quinolones against the clinical isolates used in this study. •The MIC90 of LSX against C. difficile was 8-fold less than that of MFX.•LSX showed strong activities against respiratory anaerobes and oral streptococci.•The MICs90 of LSX against S. anginosus group were similar to MEM, superior to MFX.•LSX exhibited excellent MIC90 against P. melaninogenica and P. intermedia.
doi_str_mv 10.1016/j.anaerobe.2018.08.002
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2089850170</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S107599641830146X</els_id><sourcerecordid>2089850170</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-346d0324249a4f8d2374f4113911f10d06418efda9fd8c3297d5a39d4d3007493</originalsourceid><addsrcrecordid>eNqFUUtqHDEUbEJM_EmuYLTMIj15aqk_2iWYJDYYsoi9FhrpadCgkSaSeohvE3KUnMxqxpNt4IEKqeqVimqaaworCnT4uF2poDDFNa46oNMK6kD3qrmgIPp26kb-esFj3wox8PPmMuctAKW8798052xBnNOL5s9d-Pv74EqKROniKnoi0RKvsp6tj7-UduEDUSTEA3pi_RxT_Dm7EH0MSFQobl11mJzyRG0wlEreKBdyIQeVXJwz0d4Fp-u7y9GrgnkxOP0-V2TIj5JwX6KOWs_LzaYa5Io2Kc77t82ZVT7ju5fzqnn8-uXh5ra9__7t7ubzfas546VlfDDAOt5xobidTMdGbjmlTFBqKRgYOJ3QGiWsmTTrxGh6xYThhgGMXLCr5v1x736JiLnIncsavVcBaw7ZwSSmHugIlTocqTrFnBNauU9up9KTpCCXfuRWnhLKpR8JdaCrwusXj3m9Q_NPdiqkEj4dCViTHhwmmbXDoNG4hLpIE93_PJ4BpOupQQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2089850170</pqid></control><display><type>article</type><title>In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group</title><source>Elsevier ScienceDirect Journals</source><creator>Yamagishi, Yuka ; Matsukawa, Yoko ; Suematsu, Hiroyuki ; Mikamo, Hiroshige</creator><creatorcontrib>Yamagishi, Yuka ; Matsukawa, Yoko ; Suematsu, Hiroyuki ; Mikamo, Hiroshige</creatorcontrib><description>The in vitro activities of lascufloxacin were evaluated by comparison with seven reference compounds using 412 clinical isolates of anaerobes and Streptococcus anginosus group. Lascufloxacin showed potent and broad antibacterial activities greater than those of existing quinolones against the clinical isolates used in this study. •The MIC90 of LSX against C. difficile was 8-fold less than that of MFX.•LSX showed strong activities against respiratory anaerobes and oral streptococci.•The MICs90 of LSX against S. anginosus group were similar to MEM, superior to MFX.•LSX exhibited excellent MIC90 against P. melaninogenica and P. intermedia.</description><identifier>ISSN: 1075-9964</identifier><identifier>EISSN: 1095-8274</identifier><identifier>DOI: 10.1016/j.anaerobe.2018.08.002</identifier><identifier>PMID: 30114441</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Anaerobe ; Fluoroquinolone ; Lascufloxacin</subject><ispartof>Anaerobe, 2018-12, Vol.54, p.61-64</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-346d0324249a4f8d2374f4113911f10d06418efda9fd8c3297d5a39d4d3007493</citedby><cites>FETCH-LOGICAL-c434t-346d0324249a4f8d2374f4113911f10d06418efda9fd8c3297d5a39d4d3007493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.anaerobe.2018.08.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30114441$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamagishi, Yuka</creatorcontrib><creatorcontrib>Matsukawa, Yoko</creatorcontrib><creatorcontrib>Suematsu, Hiroyuki</creatorcontrib><creatorcontrib>Mikamo, Hiroshige</creatorcontrib><title>In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group</title><title>Anaerobe</title><addtitle>Anaerobe</addtitle><description>The in vitro activities of lascufloxacin were evaluated by comparison with seven reference compounds using 412 clinical isolates of anaerobes and Streptococcus anginosus group. Lascufloxacin showed potent and broad antibacterial activities greater than those of existing quinolones against the clinical isolates used in this study. •The MIC90 of LSX against C. difficile was 8-fold less than that of MFX.•LSX showed strong activities against respiratory anaerobes and oral streptococci.•The MICs90 of LSX against S. anginosus group were similar to MEM, superior to MFX.•LSX exhibited excellent MIC90 against P. melaninogenica and P. intermedia.</description><subject>Anaerobe</subject><subject>Fluoroquinolone</subject><subject>Lascufloxacin</subject><issn>1075-9964</issn><issn>1095-8274</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFUUtqHDEUbEJM_EmuYLTMIj15aqk_2iWYJDYYsoi9FhrpadCgkSaSeohvE3KUnMxqxpNt4IEKqeqVimqaaworCnT4uF2poDDFNa46oNMK6kD3qrmgIPp26kb-esFj3wox8PPmMuctAKW8798052xBnNOL5s9d-Pv74EqKROniKnoi0RKvsp6tj7-UduEDUSTEA3pi_RxT_Dm7EH0MSFQobl11mJzyRG0wlEreKBdyIQeVXJwz0d4Fp-u7y9GrgnkxOP0-V2TIj5JwX6KOWs_LzaYa5Io2Kc77t82ZVT7ju5fzqnn8-uXh5ra9__7t7ubzfas546VlfDDAOt5xobidTMdGbjmlTFBqKRgYOJ3QGiWsmTTrxGh6xYThhgGMXLCr5v1x736JiLnIncsavVcBaw7ZwSSmHugIlTocqTrFnBNauU9up9KTpCCXfuRWnhLKpR8JdaCrwusXj3m9Q_NPdiqkEj4dCViTHhwmmbXDoNG4hLpIE93_PJ4BpOupQQ</recordid><startdate>201812</startdate><enddate>201812</enddate><creator>Yamagishi, Yuka</creator><creator>Matsukawa, Yoko</creator><creator>Suematsu, Hiroyuki</creator><creator>Mikamo, Hiroshige</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201812</creationdate><title>In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group</title><author>Yamagishi, Yuka ; Matsukawa, Yoko ; Suematsu, Hiroyuki ; Mikamo, Hiroshige</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-346d0324249a4f8d2374f4113911f10d06418efda9fd8c3297d5a39d4d3007493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anaerobe</topic><topic>Fluoroquinolone</topic><topic>Lascufloxacin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamagishi, Yuka</creatorcontrib><creatorcontrib>Matsukawa, Yoko</creatorcontrib><creatorcontrib>Suematsu, Hiroyuki</creatorcontrib><creatorcontrib>Mikamo, Hiroshige</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Anaerobe</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamagishi, Yuka</au><au>Matsukawa, Yoko</au><au>Suematsu, Hiroyuki</au><au>Mikamo, Hiroshige</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group</atitle><jtitle>Anaerobe</jtitle><addtitle>Anaerobe</addtitle><date>2018-12</date><risdate>2018</risdate><volume>54</volume><spage>61</spage><epage>64</epage><pages>61-64</pages><issn>1075-9964</issn><eissn>1095-8274</eissn><abstract>The in vitro activities of lascufloxacin were evaluated by comparison with seven reference compounds using 412 clinical isolates of anaerobes and Streptococcus anginosus group. Lascufloxacin showed potent and broad antibacterial activities greater than those of existing quinolones against the clinical isolates used in this study. •The MIC90 of LSX against C. difficile was 8-fold less than that of MFX.•LSX showed strong activities against respiratory anaerobes and oral streptococci.•The MICs90 of LSX against S. anginosus group were similar to MEM, superior to MFX.•LSX exhibited excellent MIC90 against P. melaninogenica and P. intermedia.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30114441</pmid><doi>10.1016/j.anaerobe.2018.08.002</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1075-9964
ispartof Anaerobe, 2018-12, Vol.54, p.61-64
issn 1075-9964
1095-8274
language eng
recordid cdi_proquest_miscellaneous_2089850170
source Elsevier ScienceDirect Journals
subjects Anaerobe
Fluoroquinolone
Lascufloxacin
title In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T06%3A29%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%C2%A0vitro%20activity%20of%20lascufloxacin,%20a%20novel%20fluoroquinolone%20antibacterial%20agent,%20against%20various%20clinical%20isolates%20of%20anaerobes%20and%20Streptococcus%20anginosus%20group&rft.jtitle=Anaerobe&rft.au=Yamagishi,%20Yuka&rft.date=2018-12&rft.volume=54&rft.spage=61&rft.epage=64&rft.pages=61-64&rft.issn=1075-9964&rft.eissn=1095-8274&rft_id=info:doi/10.1016/j.anaerobe.2018.08.002&rft_dat=%3Cproquest_cross%3E2089850170%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2089850170&rft_id=info:pmid/30114441&rft_els_id=S107599641830146X&rfr_iscdi=true